Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Current Investments: 2011-2024

Historic Cash & Current Investments for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $151.5 million.

  • Capricor Therapeutics' Cash & Current Investments rose 15.92% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $517.7 million, marking a year-over-year increase of 166.98%. This contributed to the annual value of $151.5 million for FY2024, which is 283.70% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Cash & Current Investments of $151.5 million as of FY2024, which was up 283.70% from $39.5 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Cash & Current Investments peaked at $151.5 million during FY2024, and registered a low of $32.7 million during FY2020.
  • For the 3-year period, Capricor Therapeutics' Cash & Current Investments averaged around $77.5 million, with its median value being $41.4 million (2022).
  • As far as peak fluctuations go, Capricor Therapeutics' Cash & Current Investments decreased by 4.67% in 2023, and later surged by 283.70% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Cash & Current Investments (Yearly) stood at $32.7 million in 2020, then rose by 6.68% to $34.9 million in 2021, then rose by 18.74% to $41.4 million in 2022, then decreased by 4.67% to $39.5 million in 2023, then spiked by 283.70% to $151.5 million in 2024.